StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell

StockNews.com lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

Several other research firms have also commented on ANIP. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.00.

ANI Pharmaceuticals Trading Up 0.9 %

Shares of ANIP opened at $59.68 on Monday. The firm’s 50-day moving average price is $57.42 and its 200-day moving average price is $58.10. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -108.51 and a beta of 0.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,300 shares of company stock worth $584,009. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ANIP. Louisiana State Employees Retirement System raised its holdings in shares of ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 300 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of ANI Pharmaceuticals by 5.2% during the third quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after purchasing an additional 464 shares during the last quarter. New York State Teachers Retirement System raised its holdings in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 6.9% during the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock valued at $5,367,000 after purchasing an additional 5,829 shares during the last quarter. Finally, Summit Global Investments raised its holdings in shares of ANI Pharmaceuticals by 154.2% during the third quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company’s stock valued at $1,176,000 after purchasing an additional 11,952 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.